The FDA approved Detour for use in percutaneous transmural arterial bypass (PTAB) to treat peripheral arterial disease (PAD) last month. This initial procedure marks the official start of the company’s targeted market release of Detour in the U.S.
PTAB with Detour enables a disruptive, novel approach to treating PAD. It enables physicians to bypass lesions in the superficial femoral artery by using stents routed through the femoral vein. This restores blood flow to the leg, effectively treating patients with long lesions (20cm-46cm in length), Endologix says. It also treats those who already underwent failed endovascular procedures or those who represent suboptimal open surgical bypass candidates.
For the rollout of the Detour system, Endologix collaborated with the Cleveland Clinic and the Salinas Valley Health Medical Center.
“We are delighted to be able to introduce PTAB using the Detour system into clinical use,” said Dr. Matt Thompson, president and CEO of Endologix. “The Detour System is a pivotal addition to our product portfolio, which now offers differentiated therapies for both abdominal aortic aneurysms and PAD. The successful introduction at these leading institutions underscores our commitment to continuing to innovate on behalf of patients.
“Broadening our therapeutic profile is a key achievement as we transform Endologix into a leading interventional vascular company.”
